Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers
Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a Phase 1 trial for patients with advanced solid tumors, including ovarian cancer. COM701 is an antibody against PVRIG — a new immune checkpoint receptor identified by Compugen with its computational predictive platform — that blocks the interaction with its ligand PVRL2. While the PVRIG receptor is highly present on the surface of T-cells — white blood cells that play key roles in fighting cancer — that infiltrate the tumor microenvironment, PVRL2 is highly present in several cancers, such as ovarian, breast, endometrial, and non-small cell lung cancer (NSCLC) tumors, suggesting that the PVRIG/PVRL2 interaction may be an important mechanism of immune suppression by these cancers. Preclinical studies have shown that blocking this interaction strongly boosts the activation of T-cells, which suggests it may activate these cells in the tumor microenvironment to generate anti-tumor immune responses. Studies in mouse models have also shown that COM701's anti-tumor effect was even stronger when combined with Opdivo, an antibody against another immune checkp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *